Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity Direct-to-Patient Platform

DxTerity has launched its Direct-to-Patient (D2P) platform for population-scale genomic studies. The D2P platform uses cost-effective, self-administered finger-stick blood collection and a nucleic acid stabilization device that can be distributed and returned via standard mail with no refrigeration required, the company said. The device stabilizes both the RNA and DNA in the blood sample enabling full genome and full transcriptome profiling. The sample, once returned, is analyzed in the company's CLIA-licensed, CAP-certified genomics laboratory. Electronic consent, electronic data capture, and electronic patient-reported outcomes are included in the D2P platform.